Flexion Therapeutics (NASDAQ:FLXN) Downgraded by BMO Capital Markets – 2 stars to Market Perform

Flexion Therapeutics} stock has undergone multiple analysts rating changes in the recent past.  Flexion Therapeutics Downgraded by BMO Capital Markets – 2 stars on 10-12-21. In a note to investors, the firm issued a new rating of Market Perform. The analysts previously had rating of Outperform.

View More Flexion Therapeutics (NASDAQ:FLXN) Downgraded by BMO Capital Markets – 2 stars to Market Perform